Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia

European Urology

Volumn 60, Issue 4, 2011, Pages 809-825

  Gacci, Mauro ^a   Eardley, Ian ^b   Giuliano, Francois ^c   Hatzichristou, Dimitris ^d   Kaplan, Steven A ^e   Maggi, Mario ^a   McVary, Kevin T ^f   Mirone, Vincenzo ^g   Porst, Hartmut ^h   Roehrborn, Claus G ⁱ  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c RAYMOND POINCARÉ HOSPITAL   (France)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Private Practice of Urology and Andrology   (Germany)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Age; Benign prostatic hyperplasia; BPH; ED; EjD; IIEF; IPSS; LUTS; PDE5; PDE5 i; Prostate

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOFLAVONOID; CAROTENOID; CYCLIC GMP; DOXAZOSIN; DUTASTERIDE; FATTY ACID; FINASTERIDE; LIGNAN; NITRIC OXIDE; PHENOL; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PHYTOESTROGEN; PLACEBO; QUERCETIN; RHO KINASE; RHOA RHO KINASE; SABAL EXTRACT; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ADRENERGIC ACTIVITY; ATHEROSCLEROSIS; AUTONOMIC INNERVATION; AUTONOMIC NERVOUS SYSTEM; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; HEALTH SURVEY; HUMAN; HYPERTHERMIC THERAPY; HYPOTHESIS; INTERSTITIAL LASER COAGULATION; LASER COAGULATION; LOWER URINARY TRACT SYMPTOM; MEDLINE; META ANALYSIS; MINIMALLY INVASIVE SURGERY; NONHUMAN; PATHOPHYSIOLOGY; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SABAL; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; CYCLIC GMP; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; META-ANALYSIS AS TOPIC; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PREVALENCE; PROSTATIC HYPERPLASIA; RHO-ASSOCIATED KINASES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 80052269812     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.037     Document Type: Review

References (133)

1. R.C. Rosen Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia Curr Opin Urol 16 2006 11 19 (Pubitemid 43041215)
2. K.T. McVary Erectile dysfunction and lower urinary tract symptoms secondary to BPH Eur Urol 47 2005 838 845 (Pubitemid 40745354)
3. F.C. Lowe Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function BJU Int 95 Suppl 4 2005 12 18 (Pubitemid 40704404)
4. S. Mouli, and K.T. McVary PDE5 inhibitors for LUTS Prostate Cancer Prostatic Dis 12 2009 316 324
5. G.J. MacFarlane, H. Botto, Sagnier P-PP, P. Teillac, F. Richard, and P. Boyle The relationship between sexual life and urinary condition in the French community J Clin Epidemiol 10 1996 1771 1776
6. R.C. Rosen, F. Giuliano, and C.C. Carson Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) Eur Urol 47 2005 824 837 (Pubitemid 40745353)
7. H.A. Feldman, I. Goldstein, D.G. Hatzichristou, R.J. Krane, and J.B. McKinlay Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 151 1994 54 61 (Pubitemid 24046934)
8. E.O. Laumann, A. Paik, and R.C. Rosen Sexual dysfunction in the United States. Prevalence and predictors JAMA 281 1999 537 544 (Pubitemid 29081307)
9. M.H. Blanker, A.M. Bohnen, and F.P. Groeneveld Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study J Am Geriatr Soc 49 2001 436 442 (Pubitemid 32390877)
10. M. Braun, G. Wassmer, T. Klotz, B. Reifenrath, M. Mathers, and U. Engelmann Epidemiology of erectile dysfunction: results of the "Cologne Male Survey." Int J Impot Res 12 2000 305 311 (Pubitemid 32175951)
11. M.K. Li, L.A. Garcia, and R. Rosen Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries BJU Int 96 2005 1339 1354 (Pubitemid 41743935)
12. R. Shiri, J. Häkkinen, J. Koskimäki, M. Hakama, T.L. Tammela, and A. Auvinen Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother Int J Impot Res 19 2007 317 320 (Pubitemid 46701456)
13. S.T. Brookes, C.L. Link, J.L. Donovan, and J.B. McKinlay Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey J Urol 179 2008 250 255 (Pubitemid 350216754)
14. E.M. Khoo, H.M. Tan, and W.Y. Low Erectile dysfunction and comorbidities in aging men: an urban cross-sectional study in Malaysia J Sex Med 5 2008 2925 2934
15. C.A. Holden, R.I. McLachlan, and M. Pitts Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS) BMC Public Health 10 2010 96
16. A. Nicolosi, D.B. Glasser, E.D. Moreira, and M. Villa Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study Int J Impot Res 5 2003 253 257 (Pubitemid 37101658)
17. P. Boyle, C. Robertson, and C. Mazzetta UrEpik Study Group. The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study BJU Int 92 2003 719 725 (Pubitemid 37475814)
18. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649 (Pubitemid 37542920)
19. A.J. Wein, K.S. Coyne, A. Tubaro, C.C. Sexton, Z.S. Kopp, and L.P. Aiyer The impact of lower urinary tract symptoms on male sexual health: EpiLUTS BJU Int 103 Suppl 3 2009 33 41
20. J. Schou, N.R. Holm, and H.H. Meyhoff Sexual function in patients with symptomatic benign prostatic hyperplasia Scand J Urol Nephrol Suppl 179 1996 119 122 (Pubitemid 26325237)
21. S. Namasivayam, S. Minhas, J. Brooke, A.D. Joyce, S. Prescott, and I. Eardley The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia Br J Urol 82 1998 842 846 (Pubitemid 28556732)
22. J. Baniel, S. Israilov, J. Shmueli, E. Segenreich, and P.M. Livne Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy Eur Urol 38 2000 53 58 (Pubitemid 30418015)
23. A. Tubaro, M. Polito, L. Giambroni, C. Famulari, E. Gange, and E. Ostardo Sexual function in patients with LUTS suggestive of BPH Eur Urol 40 Suppl 1 2001 19 22 (Pubitemid 34701701)
24. S.C. Sak, Z. Hussain, C. Johnston, and I. Eardley What is the relationship between male sexual function and lower urinary tract symptoms (LUTS)? Eur Urol 46 2004 482 487 (Pubitemid 39200857)
25. C.E. Hoesl, E.M. Woll, M. Burkart, and J.E. Altwein Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS) Eur Urol 47 2005 511 517 (Pubitemid 40357899)
26. S. Morant, G. Bloomfield, V. Vats, and C. Chapple Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms J Sex Med 6 2009 1103 1110
27. A.I. El-Sakka Lower urinary tract symptoms in patients with erectile dysfunction: analysis of risk factors J Sex Med 3 2006 144 149
28. K. McVary, K.A. Foley, S.R. Long, S. Sander, T.G. Curtice, and H. Shah Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction Curr Med Res Opin 24 2008 775 784 (Pubitemid 351428989)
29. E. Reggio, J. de Bessa Jr., and R.G. Junqueira Correlation between lower urinary tract symptoms and erectile dysfunction in men presenting for prostate cancer screening Int J Impot Res 19 2007 492 495 (Pubitemid 47367523)
30. A.A. Antunes, M. Srougi, M.F. Dall'oglio, F. Vicentini, M. Paranhos, and G.C. Freire The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening J Sex Med 5 2008 1702 1707 (Pubitemid 352044426)
31. S.J. Frankel, J.L. Donovan, and T.I. Peters Sexual dysfunction in men with lower urinary tract symptoms J Clin Epidemiol 51 1998 677 685 (Pubitemid 28404362)
32. G. Vallancien, M. Emberton, N. Harving, and R.J. van Moorselaar Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms J Urol 169 2003 2257 2261 (Pubitemid 36576765)
33. M.K. Li, L. Garcia, and N. Patron An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function BJU Int 101 2008 197 202 (Pubitemid 350294053)
34. I.I. Bouwman, W.K. Van Der Heide, K. Van Der Meer, and R. Nijman Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: are there differences between male populations from primary healthcare and urology clinics?. A review of the current knowledge Eur J Gen Pract 15 2009 128 135
35. T.S. Köhler, and K.T. McVary The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors Eur Urol 55 2009 38 48
36. A. Moon Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle in vitro BJU Int 89 2002 942 949 (Pubitemid 34535433)
37. G.T. Kedia, S. Uckert, U. Jonas, M.A. Kuczyk, and M. Burchardt The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms World J Urol 26 2008 603 609
38. J.S. Dixon, and P.Y. Jen Development of nerves containing nitric oxide synthase in the human male urogenital organs Br J Urol 76 1995 719 725
39. J.I. Gillespie, M. Markerink-van Ittersum, and J. De Vente Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells Cell Tissue Res 325 2006 325 332 (Pubitemid 44050798)
40. P. Hedlund Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - is there a basis for pharmacological targeting of cGMP? World J Urol 23 2005 362 367 (Pubitemid 43124386)
41. K. Persson, P. Alm, K. Johansson, B. Larsson, and K.E. Andersson Nitric oxide synthase in pig lower urinary tract: immunohistochemistry, NADPH diaphorase histochemistry and functional effects Br J Pharmacol 110 1993 521 530 (Pubitemid 23279255)
42. B. Fibbi, A. Morelli, and L. Vignozzi Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract J Sex Med 7 2010 59 69
43. G. Corona, E. Mannucci, G. Forti, and M. Maggi Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases Int J Androl 32 2009 587 598
44. S. Filippi, A. Morelli, and P. Sandner Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 2007 1019 1029
45. S. Oger, D. Behr-Roussel, and D. Gorny Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle Br J Pharmacol 160 2010 1135 1143
46. A. Morelli, A.K. Chavalmane, and S. Filippi Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signalling hyper-activation J Sex Med 6 2009 91 106
47. A. Morelli, L. Vignozzi, and S. Filippi BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder Prostate 67 2007 234 247
48. B. Fibbi, A. Morelli, and M. Marini Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway J Androl 29 2008 70 84
49. A. Wibberley, Z. Chen, E. Hu, J.P. Hieble, and T.D. Westfall Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle Br J Pharmacol 138 2003 757 766 (Pubitemid 36390631)
50. M. Rajasekaran, N. Wilkes, S. Kuntz, and M. E Albo Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats Neurourol Urodyn 24 2005 295 300 (Pubitemid 40617107)
51. A. Morelli, S. Filippi, and P. Sandner Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats J Sex Med 6 2009 1594 1608
52. A. Yassin, F. Saad, C.E. Hoesl, A.M. Traish, M. Hammadeh, and R. Shabsigh Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice Andrologia 38 2006 1 12
53. N.U. Rahman, S. Phonsombat, D. Bochinski, R.E. Carrion, L. Nunes, and T.F. Lue An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat BJU Int 100 2007 658 663 (Pubitemid 47205488)
54. A. Vikram, G.B. Jena, and P. Ramarao Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia Prostate 70 2010 79 89
55. E. Golomb, R. Rosen, and N. Zweig Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats J Androl 21 2000 58 64 (Pubitemid 30069082)
56. K. Persson, R.K. Pandita, J.M. Spitsbergen, W.D. Steers, J.B. Tuttle, and K.E. Andersson Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats Am J Physiol 275 1998 R1366 R1373
57. P. Montorsi, P.M. Ravagnani, and S. Galli Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient Eur Urol 50 2006 721 731 (Pubitemid 44332685)
58. A.P. Berger, M. Deibl, and N. Leonhartsberger Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction BJU Int 96 2005 1073 1078 (Pubitemid 41531417)
59. M.A. Ghafar, A.G. Anastasiadis, and L.E. Olsson Hypoxia and an angiogenic response in the partially obstructed rat bladder Lab Invest 82 2002 903 909 (Pubitemid 34761665)
60. T. Tarcan, K.M. Azadzoi, M.B. Siroky, I. Goldstein, and R.J. Krane Age-related erectile and voiding dysfunction: the role of arterial insufficiency Br J Urol 82 Suppl 1 1998 26 33
61. Z. Du, C. Fujiyama, Y. Chen, and Z. Masaki Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue Chin Med J (Engl) 116 2003 1936 1939 (Pubitemid 38159901)
62. A.G. Lekas, A.C. Lazaris, and M. Chrisofos Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia Urology 68 2006 436 441 (Pubitemid 44175515)
63. B.J. Gu, O. Ishizuka, Y. Igawa, O. Nishizawa, and K.E. Andersson Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction J Urol 167 2002 1887 1891 (Pubitemid 34240776)
64. A. Morelli, S. Filippi, and P. Comeglio Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats J Sex Med 7 2010 107 120
65. G. Penna, B. Fibbi, and S. Amuchastegui Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation J Immunol 182 2009 4056 4064
66. G. Penna, B. Fibbi, and S. Amuchastegui The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways Prostate 69 2009 480 493
67. G. Corona, and M. Maggi The role of testosterone in erectile dysfunction Nat Rev Urol 7 2010 46 56
68. D.J. Carbone Jr., and S. Hodges Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life Int J Impot Res 15 2003 299 306 (Pubitemid 37101667)
69. R.C. Rosen, J.T. Wei, S.E. Althof, A.D. Seftel, M. Miner, and M.A. Perelman BPH Registry and Patient Survey Steering Committee. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry Urology 73 2009 562 566
70. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
71. H.H.F. Leliefeld, H.J. Stoevelaar, and J. Mc Donnell Sexual function before and after various treatments for symptomatic benign hyperplasia BJU Int 89 2002 208 213 (Pubitemid 34158451)
72. J.C. Nickel, D. Shosker, C.G. Roehrborn, and M. Moyad Nutriceuticals in prostate disease: the urologist's role Rev Urol 10 2008 192 206
73. J.T. Wilt, A. Ishani, I. Rutks, and R. MacDonald Phytotherapy for benign prostatic hyperplasia Public Health Nutrition 3 2000 459 472 (Pubitemid 32095584)
74. A.R. Zlotta, P. Teillac, J.P. Raynaud, and C.C. Schulman Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon®), tamsulosin or finasteride Eur Urol 48 2005 269 276 (Pubitemid 40957102)
75. K.K. Seo, M.Y. Lee, S.W. Lim, and S.C. Kim Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists: prazosin, terazosin, doxazosin, and tamsulosin J Korean Med Sci 14 1999 69 74
76. M.M. Van Dijk, J.J. De La Rosette, and M.C. Michel Effects of alpha 1 adrenoceptor antagonists on male sexual function Drugs 66 2006 287 301 (Pubitemid 46291765)
77. H. Lepor, W.O. Williford, M.J. Barry, C. Haakenson, and K. Jones The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response J Urol 160 1998 1358 1367 (Pubitemid 29480516)
78. I. Goldstein Oral phentolamine: an alpha -1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction Int J Imp Res 12 Suppl 1 2000 S75 80
79. R. Kumar, A. Nehra, and D.J. Jacobson Alpha blocker use is associated with decreased risk of sexual dysfunction Urology 74 2009 82 87
80. T.J. Wilt, W. Howe, and R. MacDonald Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects BJU Int 89 2002 214 225 (Pubitemid 34158452)
81. R. MacDonald, T.J. Wilt, and R.W. Howe Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects BJU Int 94 2004 1263 1270 (Pubitemid 40052090)
82. K. Höfner, H. Claes, T.M. De Reijke, B. Folkestad, and M.J. Speakman Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 335 341 (Pubitemid 29419452)
83. C.G. Roehrborn, and R.C. Rosen Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Clin Interv Aging 3 2008 511 524
84. R.S. Kirby, M.P. O'Leary, and C. Carson Efficacy of extended release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction BJU Int 95 2005 103 109 (Pubitemid 350020880)
85. H. Lepor Phase III multicenter placebocontrolled study of tamsulosin in benign prostatic hyperplasia Urology 51 1998 892 900 (Pubitemid 28240845)
86. K. Kobayashi, N. Masumori, and S. Hisasue Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A-blocker in normal volunteers J Sex Med 5 2008 2185 2190
87. W.J.G. Hellstrom, and S.C. Sikka Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in healthy volunteers J Urol 76 2006 1529 1533 (Pubitemid 44307193)
88. S.I. Hisasue, R. Furuya, and N. Itoh Ejaculatory disorder induced by alpha-adrenergic receptor blockade is not retrograde ejaculation J Urol 173(Suppl) 290 2005 A1069
89. F. Giuliano, P. Clément, P. Denys, L. Alexandre, and J. Bernabé Comparison between tamsulosin and alfuzosin on expulsion phase of ejaculation in rats BJU Int 98 2006 876 879 (Pubitemid 44368043)
90. T. Yokoyama, R. Hara, and K. Fukumoto Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia Int J Urol 18 2011 225 230
91. C.R. Chapple, F. Montorsi, T.L.J. Tammela, M. Wirth, E. Koldewijn, E. Fernández Fernández on behalf of the European Silodosin Study Group Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe Eur Urol 59 2011 342 352
92. K. Kobayashi, N. Masumori, R. Kato, S. Hisasue, R. Furuya, and T. Tsukamoto Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha 1A-blocker administration Int J Imp Res 21 2009 306 310
93. Y. Homma, K. Kawabe, M. Takeda, and M. Yoshida Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia Urology 76 2010 1446 1450
94. F. Giuliano Impact of medical treatments for benign prostatic hyperplasia on sexual function BJU Int 97 Suppl 2 2006 34 38 (Pubitemid 43356994)
95. J.C. Nickel, Y. Fradet, and R.C. Boake Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT study) CMAJ 155 1996 1251 1259 (Pubitemid 26392086)
96. F. Erdemir, A. Harbin, and W.J. Hellstrom 5-alpha reductase inhibitors and erectile dysfunction: the connection J Sex Med 5 2008 2917 2924
97. C.M. Moinpour, A.K. Darke, and G.W. Donaldson Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial J Natl Cancer Inst 99 2007 1025 1035 (Pubitemid 47232603)
98. C.G. Roehrborn, P. Siami, and J. Barkin CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study J Urol 179 2008 616 621
99. H.S. Tunuguntla, and C.P. Evans Minimally invasive therapies for benign prostatic hyperplasia World J Urol 20 2002 197 206
100. R.M. Hoffman, M. Monga, S.P. Elliot, R. Macdonald, and T.J. Wilt Microwave thermotherapy for benign prostatic hyperplasia Cochrane Database Syst Rev 2007 CD004135
101. C. Bouza, T. López, A. Magro, L. Navalpotro, and J.M. Amate Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia BMC Urol 6 2006 14
102. E.D. Kursh, R. Concepcion, S. Chan, P. Hudson, M. Ratner, and R. Eyre Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up Urology 61 2003 573 578 (Pubitemid 36294194)
103. Y. Arai, Y. Aoki, and K. Okubo Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study J Urol 164 2000 1206 1211
104. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54. (Pubitemid 39345720)
105. W.K. Mebust, H.L. Holtgrewe, A.T. Cockett, and P.C. Peters Transurethral prostatectomy: immediate and postoperative complications. a cooperative study of 13 participating institutions evaluating 3,885 patients J Urol 167 2002 999 1003
106. S. Bieri, C.E. Iselin, and S. Rohner Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunctional after transurethral prostatectomy Scand J Urol Nephrol 31 1997 545 548 (Pubitemid 28020564)
107. R. Tscholl, M. Largo, E. Poppinghaus, F. Recker, and B. Subotic Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests J Urol 153 1995 1491 1493
108. J.H. Wasson, D.J. Reda, R.C. Bruskewitz, J. Elinson, A.M. Keller, and W.G. Henderson A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate N Eng J Med 332 1995 75 79
109. T. Lourenco, M. Shaw, C. Fraser, G. MacLennan, J. N'Dow, and R. Pickard The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomized controlled trials World J Urol 28 2010 23 32
110. C.G. Roehrborn Standard surgical interventions: TURP/TUIP/OPSU R. Kirby, J. McConnell, J. Fitzpatrick, Textbook of benign prostatic hyperplasia. 1996 ISIS Medical Media Oxford, UK 341 378
111. M. Soleimani, S.Y. Hosseini, M. Aliasgari, F. Dadkhah, A. Lashay, and E. Amini Erectile dysfunction after prostatectomy: an evaluation of the risk factors Scand J Urol Nephrol 43 2009 277 281
112. Q. Chen, L. Zhang, Q.L. Fan, J. Zhou, Y.B. Peng, and Z. Wang Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up BJU Int 106 2010 1339 1343
113. R. Naspro, A. Bachmann, and P. Gilling A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate Eur Urol 55 2009 1345 1357
114. A. Briganti, R. Naspro, and A. Gallina Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial J Urol 175 2006 1817 1821
115. G. Alivizatos, A. Skolarikos, and D. Chalikopoulos Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80 ml: 12-mo results of a randomized prospective study Eur Urol 54 2008 427 437
116. M.M. Miner Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ? Curr Urol Rep 10 2009 254 260
117. S.A. Ahyai, P. Gilling, and S.A. Kaplan Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement Eur Urol 58 2010 384 397
118. M. Gacci, R. Bartoletti, and S. Figlioli Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study BJU Int 91 2003 196 200 (Pubitemid 36232834)
119. F. Montorsi, J. Corbin, and S. Phillips Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention J Sex Med 1 2004 322 336 (Pubitemid 40424643)
120. C. Zhao, S.H. Kim, and S.W. Lee Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia BJU Int 107 2011 1943 1947
121. Gacci M, Del Popolo G, Macchiarella A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178:2040-3; discussion 2044.
122. M. Gacci, A. Ierardi, and A.D. Rose Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study J Sex Med 7 2010 234 243
123. M. Bertolotto, E. Trincia, R. Zappetti, R. Bernich, G. Savoca, and M.A. Cova Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US Radiol Med 114 2009 1106 1114
124. K.T. McVary, W. Monnig, J.L. Camps Jr., J.M. Young, L.-J. Tseng, and G. Van Den Eeden Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized double-blind trial J Urol 177 2007 1071 1077 (Pubitemid 46216352)
125. A. Tuncel, V. Nalcacioglu, K. Ener, Y. Aslan, O. Aydin, and A. Atan Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction World J Urol 28 2010 17 22
126. K. McVary, C. Roehborn, and J. Kaminetsky Tadalafil relieves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) J Urol 177 2007 1401 1407 (Pubitemid 46435965)
127. C.G. Roehrborn, K.T. McVary, A. Elion-Mboussa, and L. Viktrup Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study J Urol 180 2008 1228 1234
128. A. Bechara, S. Romano, and A. Casabé Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study J Sex Med 5 2008 2170 2178
129. C.G. Stief, H. Porst, D. Neuser, M. Beneke, and E. Ulbrich A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur Urol 53 2008 1236 1244
130. M. Gacci, G. Vittori, and G. Siena Long term safety and efficacy of combination therapy with vardenafil 10 mg and tamsulosin 0,4 mg for persistent irritative LUTS: a randomized double blind placebo controlled study Eur Urol Suppl 10 2011 123
131. B.H. Chung, J.Y. Lee, S.H. Lee, S.J. Yoo, S.W. Lee, and C.Y. Oh Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS Int J Impot Res 21 2009 122 128
132. M.J. Speakman PDE5 inhibitors in the treatment of LUTS Curr Pharm Des 15 2009 3502 3505
133. C. Wang Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia Curr Opin Urol 20 2010 49 54